tert-butyl (2-(isopropylamino)ethyl)(methyl)carbamate | 320581-01-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (2-(isopropylamino)ethyl)(methyl)carbamate
• 英文别名: tert-butyl N-methyl-N-{2-[(propan-2-yl)amino]ethyl}carbamate；tert-butyl N-methyl-N-[2-(propan-2-ylamino)ethyl]carbamate
• CAS: 320581-01-9
• 化学式: C₁₁H₂₄N₂O₂
• 分子量: 216.324
• InChiKey: MOLNISCZMZHODP-UHFFFAOYSA-N

物化性质

• 沸点：
  276.3±19.0 °C(Predicted)
• 密度：
  0.940±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(N-Boc-N-甲基氨基)乙醇 在 戴斯-马丁氧化剂 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 6.5h， 生成 tert-butyl (2-(isopropylamino)ethyl)(methyl)carbamate
  参考文献：
  名称：

  [EN] PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF
  [FR] PROMÉDICAMENTS D'ANALOGUES DE NEUROSTÉROÏDES ET LEURS UTILISATIONS

  摘要：

  Prodrugs of neurosteroid analogs are disclosed. Pharmaceutical formulations containing the prodrugs are also disclosed. Additionally, methods of treating a condition, disorder, or disease using the prodrugs or their pharmaceutical formulations are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, CNS injury, concussion, traumatic brain injury, depression, postpartum depression, epilepsy, seizure disorder, and neurodegenerative disease.

  公开号：

  WO2023086438A1

文献信息

• [EN] PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ALPHA, OMÉGA-DIAMINO ALCANES MONO-PROTÉGÉS
  申请人：SYNTHON BIOPHARMACEUTICALS BV

  公开号：WO2018086993A1

  公开（公告）日：2018-05-17

  The present invention relates to a process for the synthesis of mono-protected α,ω-diamino alkanes, the use of said proces in a process for the synthesis of a linker drug comprising an α,ω-diamino alkane moiety and the use of the process of the present invention in a process for preparing an antibody-drug conjugate comprising an α,ω-diamino alkane moiety.

  本发明涉及一种合成单保护的α，ω-双氨基烷的方法，以及该方法在合成含有α，ω-双氨基烷基团的连接药物的过程中的应用，以及本发明方法在制备含有α，ω-双氨基烷基团的抗体药物结合物的过程中的应用。
• AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Beijing Adamadle Biotechnology Limited Liability Company

  公开号：EP3640248A1

  公开（公告）日：2020-04-22

  The present invention relates to an aminopyrimidine compound, a preparation method therefor and use thereof. The aminopyrimidine compound has the structure as shown in formula I: the compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The present invention also relates to a pharmaceutical composition containing the compounds, a method for preparing same and the use of same in preparation of anti-tumor drugs.

  本发明涉及一种氨基嘧啶化合物、其制备方法及其用途。氨基嘧啶化合物的结构如式 I 所示： 该化合物是表皮生长因子受体（EGFR）激酶的抑制剂。本发明还涉及一种含有上述化合物的药物组合物、其制备方法和在制备抗肿瘤药物中的用途。
• Process for the preparation of mono-protected α,ω-diamino alkanes
  申请人：Byondis B.V.

  公开号：US10815194B2

  公开（公告）日：2020-10-27

  The present invention relates to a process for the synthesis of mono-protected α,ω-diamino alkanes, the use of said process in a process for the synthesis of a linker drug comprising an α,ω-diamino alkane moiety and the use of the process of the present invention in a process for preparing an antibody-drug conjugate comprising an α,ω-diamino alkane moiety.

  本发明涉及一种合成单保护α,ω-二氨基烷烃的工艺，在合成包含α,ω-二氨基烷烃分子的连接药物的工艺中使用所述工艺，以及在制备包含α,ω-二氨基烷烃分子的抗体-药物共轭物的工艺中使用本发明的工艺。
• Aminopyrimidine compound, preparation method therefor and use thereof
  申请人：BEIJING ADAMADLE BIOTECHNOLOGY LIMITED LIABILITY COMPANY

  公开号：US11352352B2

  公开（公告）日：2022-06-07

  The present invention relates to an aminopyrimidine compound, a preparation method therefor and use thereof. The aminopyrimidine compound has the structure as shown in formula I: the compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The present invention also relates to a pharmaceutical composition containing the compounds, a method for preparing same and the use of same in preparation of anti-tumor drugs.

  本发明涉及一种氨基嘧啶化合物、其制备方法及其用途。氨基嘧啶化合物的结构如式 I 所示： 该化合物是表皮生长因子受体（EGFR）激酶的抑制剂。本发明还涉及一种含有上述化合物的药物组合物、制备方法以及在制备抗肿瘤药物中的应用。
• [EN] NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS<br/>[FR] NOUVEAUX CONJUGUÉS D'ANALOGUES DE CC-1065 ET LINKERS BIFONCTIONNELS
  申请人：SYNTARGA BV

  公开号：WO2011133039A3

  公开（公告）日：2012-04-12